Narrowing R&D Focus to Themes with Clear Exit Strategies
First written in FY2018-Q2. 11 of 12 entries say "Restated". Latest entry: FY2023.
1 other company's latest entry also says "Restated".
- FY2023RestatedAnnual report
「In the regenerative medicine products segment, the company is prioritising the development of promising, high-potential candidates with a view to obtaining marketing approval at an early stage.」
Continued the policy of prioritizing development seeds with strong promise and potential to obtain approval at an early stage. - FY2023-Q1RestatedAnnual report
「In the regenerative medicine products business segment, we will prioritize the development of promising, high-potential seeds in order to obtain marketing approval at an early stage, while」
Continued the policy of prioritizing seeds with strong promise and potential to obtain approval at an early stage. - FY2022-Q2RestatedAnnual report
「In the regenerative medicine products business, we aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
Continued the R&D policy of considering the acquisition and expansion of domestic and overseas pipelines with the aim of generating revenue at an early stage. - FY2021-Q2RestatedAnnual report
「Prioritize the development of promising, high-potential seeds in order to obtain marketing approval at an early stage.」
Continued the policy of prioritizing development seeds with strong promise and potential to obtain approval at an early stage. - FY2021-Q1RestatedAnnual report
「In the regenerative medicine products segment, the company is prioritising the development of promising, high-potential candidates with a view to obtaining marketing approval at an early stage.」
Continued the policy of prioritizing development seeds with strong promise and potential to obtain approval at an early stage. - FY2020-Q3RestatedAnnual report
「In the regenerative medicine products segment, the company is prioritising the development of promising, high-potential candidates with a view to obtaining marketing approval at an early stage.」
Continued the policy of prioritizing development seeds with strong promise and potential to obtain approval at an early stage. - FY2020-Q1RestatedAnnual report
「In the regenerative medicine products business segment, the Company will prioritize the development of promising and highly viable seeds with the aim of obtaining manufacturing and marketing approval at an early stage.」
Continued the policy of prioritizing development seeds with strong promise and potential, with an exit strategy in mind. - FY2019-Q3RestatedAnnual report
「In the regenerative medicine products business segment, the Company will prioritize the development of promising and highly viable seeds with the aim of obtaining manufacturing and marketing approval at an early stage.」
Continued the policy of selecting R&D programs with an exit strategy in mind and generating revenue at an early stage, described as the development of priority seeds. - FY2019-Q2RestatedAnnual report
「We will narrow our R&D themes to those with clear exit strategies aimed at expanding our proprietary regenerative medical product pipeline and evaluating immunotherapies, with a view to generating revenue at an early stage.」
Continued the policy of focusing on R&D programs with clear exit strategies and generating revenue at an early stage. - FY2019-Q1RestatedAnnual report
「We will narrow our R&D themes to those with clear exit strategies aimed at expanding our proprietary regenerative medical product pipeline and evaluating immunotherapies, with a view to generating revenue at an early stage.」
Continued the policy of focusing on R&D programs with clear exit strategies and generating revenue at an early stage. - FY2018-Q3RestatedAnnual report
「We will narrow our R&D themes to those with clear exit strategies aimed at expanding our proprietary regenerative medical product pipeline and evaluating immunotherapies, with a view to generating revenue at an early stage.」
Continued the policy of focusing on R&D programs with clear exit strategies and generating revenue at an early stage. - FY2018-Q2First statedAnnual report
「We will narrow our R&D themes to those with clear exit strategies aimed at expanding our proprietary regenerative medical product pipeline and evaluating immunotherapies, with a view to generating revenue at an early stage.」
The Company intends to focus R&D on themes with clear exit strategies relating to pipeline expansion and immunotherapy evaluation, with a view to early monetization.